USNA Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

03
Prezzo $14.82
Capitalizzazione di Mercato (MRQ) $274M
P/E (TTM) -7.1
EPS (TTM) $-2.10
Ricavi (TTM) $927M
ROE (TTM) -7.4%
Intervallo 52 sett. $13–$28

USNA Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

04
intervallo
barre

La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.

Split azionari 3
Data ex-dividendo Split Tipo
23 Novembre 2016 2-for-1 Avanti
31 Ottobre 2003 2-for-1 Avanti
04 Agosto 1998 2-for-1 Avanti

Informazioni su USANA Health Sciences, Inc. Common Stock Panoramica della società da Wikipedia

05 · wikidata

USANA Health Sciences, Inc., or USANA, is an American direct sales company based in Salt Lake City, Utah. As of 2021, USANA was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 25 countries via a network of independent distributors.

History

In 1992, immunologist and microbiologist Myron Wentz moved his diagnostic testing company, Gull Laboratories, from Salt Lake City to West Valley City, Utah, and spun it into USANA Health Services, a multilevel marketing manufacturer of supplements. Beginning in 1993, Dallin A. Larsen served as USANA's vice president of sales (and later as a consultant to USANA's president and special advisor to the board of directors) before founding the MLM beverage company Monavie in 2005. USANA's products are not available through retail channels, and can only be obtained through one of its brand partnersor by direct order through the company.

On 20 February 2007, Barry Minkow, founder of the Fraud Discovery Institute, distributed a 500-page report to officials at the U.S. Securities and Exchange Commission (SEC), the Federal Bureau of Investigation (FBI), and the Internal Revenue Service (IRS) accusing USANA of operating an illegal pyramid scheme. The SEC conducted an investigation into USANA's business practices in March 2007 and found no evidence of wrongdoing, concluding its inquiry with no enforcement action recommended. Minkow acknowledged that he was shorting USANA's shares, hoping to profit from a drop in the stock price. In April 2007, a class action lawsuit was filed alleging that USANA's common stock had been artificially inflated. In August 2007, USANA was notified by the Securities and Exchange Commission (SEC) that its shares were subject to delisting from the NASDAQ due to its Form 10-Q, and was determined to be in compliance that October.

In January 2008, a shareholder suit was filed with allegations that USANA had misled investors about the sustainability of its growth and business model. The cases were dismissed, and the company was cleared by the U.S. Securities and Exchange Commission after an informal inquiry into the allegations, stating that it did "not intend to recommend any enforcement action by the Commission." Later that year, two Canadian USANA distributors were awarded $7 million in damages for their wrongful dismissal from the company. The firm had terminated their positions in 2003 because it believed the distributor had violated the companies' policies and procedures.

USANA filed suits against Minkow and his company claiming defamation and stock manipulation. USANA dropped the defamation suit and in March 2008 U.S. District Judge Tena Campbell threw out four of the five claims brought by USANA against Minkow ruling that USANA's claims violated California's anti-SLAPP law for suing Minkow for fair criticism and that USANA did not show a reasonable probability of winning on those claims. The remaining charge of stock manipulation was settled in July 2008, when USANA and Minkow reached an undisclosed settlement that included the removal of all USANA-related materials from the Fraud Discovery Institute website, a related Chinese website, and YouTube. Minkow also agreed to never trade in USANA's stock again.

In December 2010, USANA completed the application process to transfer its common stock listing from the NASDAQ National Market System, where it had traded since 1996, to the New York Stock Exchange. The transfer became official at the beginning of 2011. It received drug-establishment registration from the Food and Drug Administration to manufacture over-the-counter drugs later that year. In 2012, 91% of product sales were purchased by associates. The company acquired BabyCare Ltd., a China-based prenatal supplement company, in 2013 and announced plans to build a manufacturing facility in the country.

By 2018, USANA had reported record revenue due to growth in the Asia-Pacific region, though it recorded a 7% drop in net sales during its 2019 annual report. USANA has partnered with HealthCorps on health education for children and, in 2019, the USANA Foundation's Kids Eat program opened a facility to pack and distribute food for childhood hunger in the Utah area. In 2026, the Kids Eat program continued efforts to address childhood food insecurity in Utah by providing food bags to students and allowing businesses, families, and other organizations to sponsor participating schools. It was also announced as the official nutritional partner of the Spartan Race endurance brand in the United States. Its sales for the first quarter of 2020 declined by 2.3 percent compared with 2019 numbers.

The USANA Foundation was founded in 2012 and has provided hundreds of millions of meals in more than 45 countries. Their programs include USANA Kids Eat and the USANA Garden Towers.

In February 2019, the Ministry of Commerce in China suspended operations of all multi-level marketing companies and participants to conduct a 100-day review of the country's health foods industry due to exaggerated advertising claims and questionable products in the unregulated sector. Chinese departments initiated "Hundred Days of Action" to clean up the health market, where 49 products from various companies were revoked, 54 food business licenses of various companies were revoked, 90 business licenses of various companies were revoked, and 465 counterfeit and fake dens were destroyed. 85 companies, including BabyCare Ltd., a USANA subsidiary, signed a declaration to self-discipline and regulate operations, with BabyCare speaking at an event hosted by the Chinese government.

In 2024, USANA acquired a 79% stake in children's health and wellness company Hiya Health in a $260 million transaction, making Hiya a subsidiary of USANA. At the time of the acquisition, Hiya had grown to approximately $100 million in annual sales and offered eight children's health products, including multivitamins, probiotics, iron supplements, and immune support products.

Corporate affairs

Leadership

In 2007, USANA faced repeated controversy after members of its board of directors, medical advisory board and several of its executives made false statements regarding their qualifications, including education and licenses.

Founder Myron Wentz was the company's chief executive officer from 1992 until 2008, when his son, Dave Wentz, succeeded him after working in positions such as president, executive vice president, and senior vice president of strategic development. In 2015, USANA announced that the chief executive officer role would be divided between Wentz and Kevin Guest, with the former taking global operations and the latter, field development and sales. Guest was appointed the sole chief executive officer in November 2016.

Operations

USANA, a multilevel marketing company, sells its products primarily through non-employee Brand Partners, as well as through the Internet. The firm's 2010 income disclosure statement defines "associates" as those who are actively building a business, acting as wholesale buyers, or are new distributors. The firm's 2009 SEC 10-K filing distinguishes between associates and preferred customers. Associates are independent distributors of USANA products and also purchase them for personal use. Preferred customers may purchase products at wholesale prices strictly for personal use and are not permitted to resell or distribute them. As of July 2011, the firm had 222,000 active Associates and 68,000 preferred customers. It manufactured 90% of its products at the Salt Lake City headquarters, which produced more than 22 million tablets each week.

Associates may be eligible to receive commissions based on their own product sales as well as through sales made by any new distributors they recruit. According to documentation from USANA corporate, 87 percent of associates fail to make enough from commissions to recover the cost of their qualifying purchases with 67 percent of all associates making no commission; the top 2.31 percent of associates earns 72.2 percent of the company's commissions. According to a 2011 article published by the Salt Lake City Tribune, the firm's FY09 income disclosure statement indicated that the average yearly income of the company's 165,710 associates, which includes those just starting, was $617, while the "top-of-the-pyramid distributors earn an average of $857,865 annually".

USANA sells nutritional, personal care, and food products through Brand Partners and online channels.

USANA classifies Brand Partners and Preferred Customers in its core nutritional business as active customers. There were 387,000 active customers as of January 2026. In 2025, Brand Partners and Preferred Customers each made up about half of all active customers.

Sponsorships

USANA has been a paid sponsor of various athletic organizations. USANA offers an "Athlete Guarantee Program" to select sponsored athletes. The program permits selected participants to enter into an agreement with the company stipulating that, should an athlete enrolled in the program test positive for a banned substance (included in World Anti-Doping Agency regulations) as a result of taking USANA products, the company will compensate the athlete up to two times his or her current annual earnings up to $1 million USD.

In 2006, USANA signed a co-sponsorship agreement with the WTA Tour and extended it in 2011. The agreement provides athletes with nutritional supplements that are guaranteed to conform to the Tour's antidoping policy. As part of the agreement in 2011, USANA donated $1 to Children's Hunger Fund for every ace scored at a WTA tournament beginning at Wimbledon and continuing through the end of the season. USANA provided its products to 40 athletes at the Turin Olympics and worked with various sports organizations, including the Professional Rodeo Cowboys Association.

In 2003, USANA became the title sponsor of the USANA Amphitheatre, an outdoor amphitheatre based in West Valley City, Utah with a seating capacity of 20,000. In May 2012, United Concerts announced a continued naming rights partnership with USANA Health Sciences through March 2018.

In 2020, USANA became the title partner of U.S. Ski & Snowboard's training and education facility, the Center of Excellence. The facility is a training hub used by Olympians, youth athletes, and various international competitions.

In the lead-up to the 2020 Summer Olympics, USANA announced partnerships with USA Swimming and the USA Skateboarding National Team. It was the official multivitamin sponsor of USA Swimming and official nutritional supplement supplier of USA Skateboarding. The partnerships reportedly extended into multi-year agreements.

Products

USANA produces three product lines: USANA Nutritionals (Cellsentials, Optimizers, and Digestion/Detox nutritional supplements), USANA Diet & Energy (Reset meal replacement shakes, protein bars, and Rev3 energy drinks), and Sensé & Celavive personal care (skin care, skin treatment, and hair & body care products).

USANA Essentials were tested in 2011 by ConsumerLab.com in its Multivitamin and Multimineral Supplements Review of 38 leading multivitamin/multimineral products sold in the U.S. and Canada. The Essentials passed ConsumerLab's test, which included testing of selected index elements, their ability to disintegrate in solution per United States Pharmacopeia guidelines, lead contamination threshold set in California Proposition 65, and meeting U.S. Food and Drug Administration (FDA) labeling requirements.

USANA began using InCelligence Technology in August 2016 and registered it as a U.S. trademark in March 2017. The technology is used in the company's CellSentials nutritional supplement system, including its Core Minerals and Vita-Antioxidant products, which USANA markets as using its InCelligence Complex to support cellular protection and renewal. As of 2019, its products are marketed in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, the United Kingdom, the Caribbean, Puerto Rico, Philippines, France, China, Spain, Italy, Germany, Romania, Denmark, Colombia and Indonesia.

Reception

From 2004 to 2006, USANA was named on Forbes "200 Best Small Companies" list. In 2007, a Forbes article quoted industry experts and government officials who had raised questions about the cost of USANA's supplements and its business practices. Radio-Canada later aired an investigative report that examined the company's products, pricing and "misleading income claims" made to potential associates concerning revenue. It included hidden-camera footage of recruitment and other sessions, which found one group of associates appeared to violate the company's policies and distributor agreements. This contrasted with the Canadian legal requirements for multi-level marketing companies to provide clear, frequent and complete information about the revenue of the typical participant. In addition, the same group of associates were filmed making recommendations for using USANA products to treat illnesses including leukemia.

John Cloud, senior writer for Time Magazine, evaluated nutritional supplements in which he took a regimen of USANA pills, protein bars, powder drinks and psyllium fiber as recommended by the company's online evaluation. Cloud took a blood test before starting the products to measure levels of calcium, protein, sodium, cholesterol, glucose, and other substances, and was then tested again five months after starting the supplement regimen, which included 3,000 pills at a cost of $1,200. The follow-up test revealed a change in only two values; a 75% increase in vitamin D levels (attributed to the vitamin D3 supplement Cloud had been taking) and a 28 mg/dl increase in high-density lipoprotein, which could not be accounted for. Cloud also experienced a placebo response where that act of taking the supplements made him feel more vigorous despite no physiological reasons being present. This response also led to a 10-lb weight gain, as the belief that he was more vigorous led him to make poorer dietary decisions—a phenomenon referred to as the "licensing effect".

New Zealand government statistician for the Commerce Commission, Murray H. Smith, who served as an expert witness in every pyramid scheme case brought by the Commission preceding 10 years, opined in 2008 that very few USANA distributors are likely to become wealthy, and stated, "you can make a very strong argument that this could be a pyramid scheme." When asked by the National Business Review to review the firm's business structure and compensation plan, it was Smith's opinion, from a statistical not legal standpoint, that the firm demonstrated a number of characteristics commonly occurring in pyramid schemes including that most members recoup less than what they pay to participate; that those at the top of the structure are more likely to make more than those on the bottom of the structure; and that as the company grows it will become harder to recruit others. Smith also noted the company's significant turnover in distributors making it necessary to continually recruit.

Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗

Wikidata ↗

settoreConsumer products industriaConsumer products dipendenti1.570 paeseUS

Performance decennale Andamento di ricavi, utile netto, margini e EPS

06
Ricavi$925M
2016-12-31 → 2026-01-03
EPS$0.58
2016-12-31 → 2026-01-03
Flusso di cassa libero$9M
2016-12-31 → 2026-01-03
Margine netto-4.2%
2016-12-31 → 2026-01-03
Valutazione e Rapporti 07–12

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Metrica Tendenza 5 anni USNA media 5 anni Mediana dei peer Verdetto
P/E (TTM) -7.1media 5 anni ≈19.7 ≈19.7 · ·
P/S (TTM) 0.3media 5 anni ≈1.0 ≈1.0 1.2 Sottovalutato
P/B (MRQ) 0.5media 5 anni ≈2.3 ≈2.3 2.4 Sottovalutato
Prezzo / FCF (TTM) -16.8media 5 anni ≈20.5 ≈20.5 · ·
Prezzo / Flusso di cassa (TTM) -157.2media 5 anni ≈13.5 ≈13.5 16.8 Valore equo
Prezzo / Valore contabile tangibile (MRQ) 0.7media 5 anni ≈3.0 ≈3.0 · ·

La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.

valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

14
Sorpresa media -21.9%
Prossimo report Ott 19, 2026
PeriodoRapportoEPS ActualEPS StimatoSorpresa
30 Giugno 2026 Lug 20, 2026 $-0.07 $0.44 -116.0%
31 Marzo 2026 $0.61 $0.45 35.9%
31 Dicembre 2025 $0.60 $0.42 43.5%
30 Settembre 2025 $-0.15 $0.48 -131.3%
30 Giugno 2025 $0.74 $0.55 34.4%
31 Marzo 2025 $0.73 $0.71 2.2%

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

15
Conto Economico 18
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue $925M$855M$921M$999M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B$918M$790M
Cost of Revenue $201M$161M$177M$194M$218M$209M$188M$201M$179M$180M$160M$141M
Gross Profit $724M$693M$744M$805M$969M$926M$873M$989M$868M$826M$759M$650M
R&D Expense $11M$12M$11M$12M$11M$11M$10M$10M$9M$9M$6M$5M
SG&A Expense $337M$263M$257M$262M$279M$261M$268M$275M$265M$234M$209M$185M
Operating Expenses $687M$627M$651M$697M$798M$749M$727M$800M$735M$687M$617M$534M
Operating Income $37M$66M$93M$108M$170M$176M$146M$188M$133M$139M$142M$116M
Interest Expense ··$262.0K$192.0K$57.0K$507.0K$66.0K$36.0K$46.0K$444.0K$15.0K$129.0K
Interest Income $2M$11M$10M$4M$3M$3M$5M$4M$2M$1M$1M$500.0K
Other Non-op $3M$-1M$7.0K$-3M$-2M$-571.0K$-335.0K$-1M$-3.0K$-1M$-174.0K$-820.0K
Pretax Income $42M$76M$102M$109M$171M$178M$150M$192M$135M$139M$143M$116M
Income Tax $30M$34M$39M$39M$54M$53M$50M$65M$72M$39M$48M$39M
Net Income $11M$42M$64M$69M$117M$125M$101M$126M$63M$100M$95M$77M
EPS (Basic) $0.58$2.20$3.31$3.60$5.78$5.89$4.44$5.24$2.57$4.14$3.72$2.90
EPS (Diluted) $0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99$3.59$2.80
Shares (Basic) 18,535,00019,103,00019,250,00019,254,00020,146,00021,156,00022,644,00024,105,00024,349,00024,185,00025,460,00026,443,000
Shares (Diluted) 18,574,00019,162,00019,345,00019,310,00020,343,00021,256,00022,818,00024,642,00024,708,00025,047,00026,355,00027,377,000
EBITDA $70M$81M$106M$121M$183M$190M$161M$205M$149M$152M$152M$125M
Stato Patrimoniale 26
Metrica Tendenza 202520242023202220212020201920182017201620152014
Cash & Equivalents $158M$182M$330M$288M$240M$312M$235M$214M$247M$176M$143M$111M
Receivables $4M···········
Inventory $103M$70M$61M$67M$98M$90M$69M$82M$63M$65M$66M$45M
Prepaid Expense $23M$28M$26M$29M$27M$23M$26M$33M$30M$37M$35M$35M
Other Current Assets $5M$5M$6M$7M$4M$5M$5M$7M$5M$6M$5M$6M
Current Assets $288M$279M$418M$384M$365M$425M$329M$392M$340M$278M$244M$191M
PP&E (Net) $94M$95M$100M$98M$102M$100M$95M$92M$103M$101M$88M$71M
PP&E (Gross) ··$212M$210M$211M$199M$181M$178M$177M$164M$120M$114M
Accum. Depreciation $135M$130M$129M$125M$122M$116M$105M$96M$86M$76M$71M$64M
Goodwill $138M$144M$17M$17M$18M$17M$17M$17M$17M$17M$17M$18M
Intangibles $133M$152M$30M$32M$30M$31M$30M$32M$35M$34M$38M$41M
Other Non-current Assets $62M$59M$55M$55M$58M$62M$43M$18M$21M$22M$25M$24M
Total Assets $743M$748M$633M$597M$578M$641M$517M$554M$519M$471M$423M$351M
Accounts Payable $17M$12M$10M$11M$14M$18M$13M$10M$12M$9M$10M$8M
Accrued Liabilities $10M$14M$10M·········
Current Liabilities $129M$140M$119M$144M$161M$168M$136M$149M$141M$138M$131M$109M
Capital Leases $12M$10M$5M$8M$10M·$17M·····
Deferred Tax $5M$4M$5M$4M$7M$12M$10M$13M$14M$5M$10M$11M
Other Non-current Liabilities $23M$18M$12M$14M$14M$19M$19M$1M$1M$1M$1M$1M
Total Liabilities $157M$162M$136M·········
Common Stock $18.0K$19.0K$19.0K$19.0K$19.0K$21.0K$22.0K$24.0K$24.0K$24.0K$25.0K$13.0K
Retained Earnings $466M$479M$445M$392M$345M$383M$306M$330M$288M$265M$215M$166M
AOCI $-16M$-23M$-14M$-13M$458.0K$-4M$-14M$-10M$-1M$-12M$-4M$2M
Stockholders' Equity $533M$532M$497M$434M$395M$442M$352M$391M$363M$325M$281M$230M
Liabilities + Equity $743M$748M$633M$597M$578M$641M$517M$554M$519M$471M$423M$351M
Shares Outstanding 18,281,00019,064,00019,130,00019,206,00019,393,00021,038,00021,655,00023,567,00024,024,00024,485,00024,976,00025,266,000
Flusso di cassa 16
Metrica Tendenza 202520242023202220212020201920182017201620152014
D&A $33M$15M$13M$13M$13M$14M$15M$17M$16M$13M$10M$9M
Stock-based Comp $14M$15M$15M$13M$14M$14M$16M$15M$15M$17M$11M$10M
Deferred Tax $-7M$-7M$-3M$-7M$-3M$-2M$-4M$607.0K$19M$-4M$-3M$-1M
Amort. of Intangibles $19M$2M$2M$2M$1M$1M$1M$2M$1M$2M$900.0K$431.0K
Restructuring $6M$0$0·········
Other Non-cash $-28M$-3M$-18M$15M$-20M$10M$-442.0K$-7M$10M$11M$-2M$11M
Operating Cash Flow $22M$61M$71M$104M$121M$160M$127M$152M$124M$137M$111M$105M
CapEx $14M$10M$14M$10M$13M$15M$17M$11M$13M$33M$24M$20M
Investing Cash Flow $-10M$-213M$-12M$-12M$-14M$-34M$47M$-69M$-13M$-32M$-25M$-16M
Stock Repurchased $28M$9M$12M$25M$178M$57M$150M$105M$50M$65M$61M$139M
Net Stock Activity $-28M$-9M$-12M$-25M$-178M$-57M$-150M$-105M$-50M$-65M$-61M$-139M
Financing Cash Flow $-41M$10M$-14M$-30M$-181M$-59M$-152M$-105M$-50M$-65M$-49M$-113M
Net Change in Cash $-23M$-149M$42M$48M$-72M$78M$20M$-33M$72M$32M$32M$-26M
Taxes Paid $37M$40M$42M·········
Free Cash Flow $9M$51M$56M$94M$108M$145M$110M$141M$111M$104M$88M$85M
Levered FCF ··$56M$93M$108M$145M$110M$141M$111M$104M$88M$85M
Redditività 8
Metrica Tendenza 202520242023202220212020201920182017201620152014
Gross Margin 78.3%81.1%80.8%80.6%81.6%81.6%82.3%83.1%82.9%82.1%82.6%82.2%
Operating Margin 4.0%7.8%10.1%10.8%14.3%15.6%13.8%15.8%12.7%13.8%15.4%14.7%
Net Margin 1.2%4.9%6.9%6.9%9.8%11.0%9.5%10.6%6.0%9.9%10.3%9.7%
Pretax Margin 4.5%8.9%11.1%10.9%14.4%15.7%14.2%16.1%12.9%13.8%15.5%14.6%
EBITDA Margin 7.6%9.5%11.5%12.1%15.4%16.8%15.2%17.2%14.2%15.1%16.5%15.8%
ROA 1.4%6.1%10.4%11.8%19.1%21.5%18.8%23.5%12.6%22.4%24.5%21.3%
ROE 2.0%7.9%13.2%16.4%29.3%30.0%30.2%30.5%17.2%33.0%37.0%31.2%
ROIC 1.9%6.9%11.7%15.8%29.4%28.0%27.8%31.7%16.9%30.8%33.5%33.4%
Liquidità e Solvibilità 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Current Ratio 2.22.03.52.72.32.52.42.62.42.01.91.8
Quick Ratio 1.21.32.82.01.51.91.71.41.81.31.11.0
Interest Coverage ··355.2560.52985.8348.12215.05232.02880.5312.29444.1900.0
Efficienza 2
Metrica Tendenza 202520242023202220212020201920182017201620152014
Asset Turnover 1.21.21.51.71.92.02.02.22.12.32.42.2
Inventory Turnover 2.32.52.72.32.32.22.52.82.82.82.93.0
Per Azione 5
Metrica Tendenza 202520242023202220212020201920182017201620152014
Book Value / Share $29.16$27.91$25.99$22.62$20.37$20.99$16.24$16.60$15.12$13.29$22.49$18.22
Revenue / Share $49.81$44.59$47.61$51.71$58.32$53.38$46.49$48.26$42.39$40.17$69.70$57.74
Cash Flow / Share $1.20$3.18$3.65$5.38$5.96$7.55$5.55$6.17$5.01$5.47$8.46$7.68
Cash / Share $8.66$9.53$17.27$15.02$12.37$14.83$10.84$9.09$10.29$7.18$11.47$8.80
EPS (TTM) $0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99$3.59$2.80
Tassi di Crescita 9
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue YoY 8.3%-7.2%-7.8%-15.8%4.6%·······
Revenue CAGR 3Y -2.5%-10.4%-6.7%·········
Revenue CAGR 5Y -4.0%···········
EPS YoY -73.5%-33.6%-8.1%-37.4%-2.2%·······
EPS CAGR 3Y -45.5%-27.4%-17.4%·········
EPS CAGR 5Y -37.0%···········
Net Income YoY -74.4%-34.1%-8.0%-40.5%-6.5%·······
Net Income CAGR 3Y -46.3%-28.8%-20.0%·········
Net Income CAGR 5Y -38.7%···········
Valutazione (TTM) 10
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue TTM $925M$855M$921M$999M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B$918M$790M
Net Income TTM $11M$42M$64M$69M$117M$125M$101M$126M$63M$100M$95M$77M
Market Cap $355M$680M$1.03B$1.02B$1.96B$1.62B$1.73B$2.71B$1.78B$1.50B$798M$646M
P/E 33.516.316.214.817.713.218.122.529.315.317.818.3
P/S 0.40.81.11.01.71.41.62.31.71.50.90.8
P/B 0.71.32.12.45.03.74.96.94.94.62.82.8
P / Tangible Book 1.42.92.32.75.74.1······
P / Cash Flow 15.911.214.59.816.210.113.717.814.410.97.26.1
P / FCF 41.713.418.310.918.111.215.719.316.114.49.17.6
Earnings Yield 3.0%6.1%6.2%6.8%5.7%7.6%5.5%4.5%3.4%6.5%5.6%5.5%

Periodo più recente a sinistra · valori nulli mostrati come ·

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

16
Metrica 2026-01-032024-12-282023-12-302022-12-312022-01-01
Ricavi $925M $855M $921M $999M $1.19B
Margine Lordo % 78.3% 81.1% 80.8% 80.6% 81.6%
Margine Operativo % 4.0% 7.8% 10.1% 10.8% 14.3%
Utile netto $11M $42M $64M $69M $117M
EPS Diluito $0.58 $2.19 $3.30 $3.59 $5.73

Proprietari istituzionali (13F) 151 filer · $260.7M totale · Aggiornato al 30 Settembre 2026

17

Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.

Detentori 151
Valore detenuto $260.7M
Nuove posizioni 25
Posizioni chiuse 17
Attività istituzionale — Q2 2026 vs trimestre precedente
Nuove posizioni Posizioni chiuse Aumentato Diminuito Variazione netta delle azioni
25 (-5 vs trimestre precedente) 17 (+8 vs trimestre precedente) 60 (+21 vs trimestre precedente) 30 (-19 vs trimestre precedente) +1.2M

Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.

Istituzione Valore Azioni % di 13F tracciati Tipo
BlackRock, Inc. $33.181.935 1.554.189 12,73% Azioni
PZENA INVESTMENT MANAGEMENT LLC $25.739.282 1.205.587 9,87% Azioni
RENAISSANCE TECHNOLOGIES LLC $20.464.402 958.520 7,85% Azioni
VANGUARD GROUP INC $18.340.623 934.316 7,03% Azioni
DIMENSIONAL FUND ADVISORS LP $17.878.705 837.426 6,86% Azioni
Nantahala Capital Management, LLC $17.295.080 810.074 6,63% Azioni
VANGUARD CAPITAL MANAGEMENT LLC $10.405.350 487.370 3,99% Azioni
Creative Planning $8.923.681 417.971 3,42% Azioni
AQR CAPITAL MANAGEMENT LLC $8.712.637 408.086 3,34% Azioni
VANGUARD PORTFOLIO MANAGEMENT LLC $7.758.099 363.377 2,98% Azioni
GEODE CAPITAL MANAGEMENT, LLC $6.047.019 283.165 2,32% Azioni
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $5.811.641 272.208 2,23% Azioni
STATE STREET CORP $5.577.474 261.240 2,14% Azioni
Nuveen, LLC $5.112.835 239.477 1,96% Azioni
AMERICAN CENTURY COMPANIES INC $3.999.880 187.348 1,53% Azioni
JACOBS LEVY EQUITY MANAGEMENT, INC $3.855.105 180.567 1,48% Azioni
TWO SIGMA INVESTMENTS, LP $3.533.724 165.514 1,36% Azioni
MORGAN STANLEY $3.509.150 164.363 1,35% Azioni
D. E. Shaw & Co., Inc. $3.348.427 156.835 1,28% Azioni
Allianz Asset Management GmbH $3.040.219 142.399 1,17% Azioni
BRIDGEWAY CAPITAL MANAGEMENT, LLC $2.949.567 138.153 1,13% Azioni
ALGERT GLOBAL LLC $2.813.033 131.758 1,08% Azioni
GOLDMAN SACHS GROUP INC $2.631.750 123.267 1,01% Azioni
UBS Group AG $2.474.166 115.886 0,95% Azioni
LAZARD ASSET MANAGEMENT LLC $2.077.590 97.311 0,80% Azioni
NORTHERN TRUST CORP $2.016.870 94.467 0,77% Azioni
AMERIPRISE FINANCIAL INC $1.552.893 72.735 0,60% Azioni
VANGUARD FIDUCIARY TRUST CO $1.549.540 72.578 0,59% Azioni
Vanguard Global Advisers, LLC $1.514.569 70.940 0,58% Azioni
Empowered Funds, LLC $1.499.902 70.253 0,58% Azioni
TWO SIGMA ADVISERS, LP $1.289.691 65.700 0,49% Azioni
Bank of New York Mellon Corp $1.104.521 51.734 0,42% Azioni
Quantinno Capital Management LP $1.072.261 50.223 0,41% Azioni
BANK OF AMERICA CORP /DE/ $967.539 45.318 0,37% Azioni
ROYCE & ASSOCIATES LP $884.039 41.407 0,34% Azioni
DEUTSCHE BANK AG\ $821.975 38.500 0,32% Azioni
Assenagon Asset Management S.A. $815.848 38.213 0,31% Azioni
BARCLAYS PLC $777.141 36.400 0,30% Azioni
STRS OHIO $723.765 33.900 0,28% Azioni
Skopos Labs, Inc. $673.696 38.563 0,26% Azioni
HSBC HOLDINGS PLC $672.758 31.960 0,26% Azioni
Invesco Ltd. $670.775 31.418 0,26% Azioni
SEI INVESTMENTS CO $641.513 30.047 0,25% Azioni
XTX Topco Ltd $625.320 29.289 0,24% Azioni
CITADEL ADVISORS LLC $575.617 26.961 0,22% Azioni
MILLENNIUM MANAGEMENT LLC $570.728 26.732 0,22% Azioni
Verdad Advisers, LP $556.552 26.068 0,21% Azioni
Inspire Investing, LLC $512.954 29.362 0,20% Azioni
Sanctuary Advisors, LLC $497.113 23.284 0,19% Azioni
Man Group plc $489.854 22.944 0,19% Azioni

Mostra tutti i 151 proprietari istituzionali →

Attivisti e proprietari del 5%+ 3 partecipazioni

18

Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.

Depositante Depositato Partecipazione Stato Scopo Deposito
Gull Global Limited, Myron W. Wentz ×11 depositi 30 Marzo 2026 40,10% Modifica M&A / vendita SEC
Gull Holdings, Ltd., Myron W. Wentz, David A. Wentz, Jacquelyn R. Wentz, Bryan Wentz, Annette Wentz, Paul & Jane Meyer Family Foundation, Paul James Meyer, Alice Jane Meyer, Centre Island Properties, Ltd., Waco Boys Club Foundation, Inc., L-K Marketing Group, LLC, Beagle Irrevocable Asset Trust 23 Maggio 2008 · Deposito iniziale · SEC
Paul & Jane Meyer Family Foundation 20 Maggio 2008 · Deposito iniziale Investimento passivo SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Insider aziendali 38 insider · 20 dirigenti · 13 direttori

19
Insider Ruolo Ultima attività Azioni possedute Acquisti 12m Vendite 12m Netto 12m
Jim Brown CEO & PRESIDENT 24 Luglio 2025 M 16.934 0 0 $0
Doug G Iiekking CHIEF FINANCIAL OFFICER 27 Maggio 2026 S 0 0 1 $-100.500
Jeffrey Yates Chief Financial Officer 28 Ottobre 2010 M 0 0 0 $0
Deborah Woo President of Asia 08 Settembre 2016 M 1.479 0 0 $0
Fred W Cooper President and COO 28 Ottobre 2010 M 0 0 0 $0
Walter Noot CHIEF OPERATING OFFICER 27 Febbraio 2026 M 9.256 0 0 $0
Roy Truett Chief Operating Officer 27 Luglio 2012 M 0 0 0 $0
Kathryn Michelle Armstrong CHIEF SCIENTIFIC OFFICER 25 Luglio 2026 M 3.471 0 0 $0
Peter Benedict CHIEF INFORMATION OFFICER 25 Luglio 2026 M 422 0 2 $-144.236
Brent Neidig CHIEF COMMERCIAL OFFICER 16 Giugno 2026 S 0 0 3 $-147.749
Paul A. Jones CHIEF PEOPLE OFFICER 08 Giugno 2026 S 0 0 2 $-231.984
Joshua Foukas CHIEF LEGAL OFFICER 07 Maggio 2026 S 0 0 2 $-170.336
David Mulham Mulham CHIEF SALES OFFICER 10 Dicembre 2025 S 8.387 0 1 $-18.333
Daniel A. Macuga CHIEF COMMUNICATIONS OFFICER 02 Maggio 2024 S 0 0 0 $0
Robert A Sinnott CHIEF SCIENTIFIC OFFICER 05 Marzo 2024 S 0 0 0 $0
James Bramble Chief Legal Officer and Sec 05 Febbraio 2018 A 2.076 0 0 $0
Dave Wentz Co-C.E.O. 16 Agosto 2016 M 384.883 0 0 $0
Rick Stambaugh Chief Information Officer 17 Dicembre 2015 M 0 0 0 $0
Mark H Wilson E.V.P. of Sales 28 Ottobre 2010 M 5.000 0 0 $0
Bradford Richardson E.V.P. of Asia Pacific 25 Febbraio 2008 S 0 0 0 $0
Xia Ding Direttore 23 Luglio 2026 M 8.278 0 0 $0
John Turman Fleming Direttore 23 Luglio 2026 M 5.862 0 2 $-78.560
Peggie Pelosi Direttore 23 Luglio 2026 M 6.061 0 0 $0
Scott J Nixon Direttore 23 Luglio 2026 M 11.445 0 0 $0
Frederic J Winssinger Direttore 23 Luglio 2026 M 9.733 0 1 $-38.420
Timothy E Wood Direttore 23 Luglio 2026 M 11.837 0 0 $0
Gilbert A Fuller Direttore 23 Luglio 2026 M 1.632 0 3 $-60.414
Robert Auciaux Direttore 09 Maggio 2022 M 8.092 0 0 $0
Feng Peng Direttore 28 Aprile 2021 M 755 0 0 $0
Myron W. Wentz Direttore 04 Febbraio 2019 S 9.865.614 0 0 $0
Jerry G Mcclain Direttore 04 Marzo 2016 M 0 0 0 $0
Ronald S Poelman Direttore 08 Febbraio 2016 A 0 0 0 $0
Denis E Waitley Direttore 03 Novembre 2006 M 0 0 0 $0
Gull Global Limited Proprietario del 10% 04 Febbraio 2019 S 9.865.614 0 0 $0
GULL HOLDINGS LTD Proprietario del 10% 01 Aprile 2015 J 6.491.110 0 0 $0
Kevin Guest · 27 Febbraio 2026 M 45.381 0 0 $0
Donald R. Williams · 01 Maggio 2017 A · 0 0 $0
Doug Braun · 16 Dicembre 2015 M 0 0 0 $0

Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato

Proprietà ETF Posseduti da 22 ETF

20

Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.

Fondo Peso Unità Aggiornato al Fonte
VFVA · VANGUARD WELLINGTON FUND 0,11% 45.046 SH 19 Agosto 2026 Giornaliero
EBIT · Harbor ETF Trust 0,07% 367 NS 31 Luglio 2026 N-PORT
IWC · iShares Trust 0,04% 37.870 SH 11 Settembre 2026 Giornaliero
VDC · VANGUARD WORLD FUND 0,03% 128.565 SH 19 Agosto 2026 Giornaliero
VTWV · VANGUARD SCOTTSDALE FUNDS 0,02% 9.639 SH 19 Agosto 2026 Giornaliero
DFSV · Dimensional ETF Trust 0,02% 67.386 NS 31 Luglio 2026 N-PORT
PRFZ · Invesco Exchange-Traded Fund Trust 0,01% 24.234 SH 01 Ottobre 2026 Giornaliero
DFAT · Dimensional ETF Trust 0,01% 67.428 NS 31 Luglio 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0,01% 64.278 SH 19 Agosto 2026 Giornaliero
RSSL · Global X Funds 0,01% 5.337 NS 31 Luglio 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0,01% 1.189 SH 01 Ottobre 2026 Giornaliero
DFAS · Dimensional ETF Trust 0,01% 42.099 NS 31 Luglio 2026 N-PORT
IWM · iShares Trust 0,01% 283.783 SH 11 Settembre 2026 Giornaliero
DFAC · Dimensional ETF Trust 0,00% 19.278 NS 31 Luglio 2026 N-PORT
ITOT · iShares Trust 0,00% 22.756 SH 11 Settembre 2026 Giornaliero
IWV · iShares Trust 0,00% 3.720 SH 03 Settembre 2026 Giornaliero
DFUS · Dimensional ETF Trust 0,00% 1.784 NS 31 Luglio 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0,00% 124.681 SH 19 Agosto 2026 Giornaliero
VTI · VANGUARD INDEX FUNDS 0,00% 350.035 SH 19 Agosto 2026 Giornaliero
VTHR · VANGUARD SCOTTSDALE FUNDS 0,00% 790 SH 19 Agosto 2026 Giornaliero
IWN · iShares Trust · 101.470 SH 11 Settembre 2026 Giornaliero
SMLF · iShares Trust · 22.964 SH 11 Settembre 2026 Giornaliero

USNA Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

21
rating · 6 analisti VENDI
Target mediano $25.00 +68,7%
0 0,0% Acquisto forte
0 0,0% Compra
3 50,0% Mantieni
1 16,7% Vendi
2 33,3% Vendita forte

Target Price a 12 Mesi

1 analisti · 2026-10-01

Target medio $25.00 +68,7%

Basso$25.00 Media$25.00 Alto$25.00

Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore

22

Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.

Ticker Capitalizzazione di Mercato P/E Rev YoY Margine Netto ROE Margine lordo
USNA $355M 33.5 8.3% 1.2% 2.0% 78.3%
EPC $946M 38.4 -1.3% 1.1% 1.7% 41.6%
BRBR $4.39B 21.6 16.1% 9.3% -72.0% 33.3%
HNST $291M -18.4 -1.9% -4.2% -8.8% 33.3%
NUS · 3.0 -14.3% 10.8% 22.0% 69.5%
NAGE $507M 31.8 29.9% 13.4% 24.7% 64.3%
NATR $378M 20.4 5.7% 4.1% 12.0% 72.4%
MED $117M -6.3 -36.0% -4.8% -9.0% 71.3%

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi

26

Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.

La tua selezione è salvata e ti segue su tutti i ticker.

Fonte: SEC 10-Q depositato Ago 13, 2026